World Journal of **Diabetes**

World J Diabetes 2024 October 15; 15(10): 2002-2156





Published by Baishideng Publishing Group Inc

World Journal of Diabetes

Contents

Monthly Volume 15 Number 10 October 15, 2024

EDITORIAL

2002	Potential mechanism of teneligliptin in the treatment of diabetic cardiomyopathy								
	Guo J, Cao Y, Wu QY, Cen LS								
2006	Utilising continuous glucose monitoring for glycemic control in diabetic kidney disease Veeranki V, Prasad N								
2010	Potential prospects of Chinese medicine application in diabetic retinopathy <i>Zhou YM, Cao YH, Guo J, Cen LS</i>								
2015	Don't give up on mitochondria as a target for the treatment of diabetes and its complications <i>Cortés-Rojo C, Vargas-Vargas MA</i>								
2022	Immunotherapy in type 1 diabetes: Novel pathway to the future ahead <i>Ray S, Palui R</i>								

2036 Surgical or medical treatment of obesity-associated type 2 diabetes-an increasing clinical conundrum Jalleh RJ, Jones KL, Islam MS, Cai L, Horowitz M

REVIEW

2041 Role of cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes pathway in diabetes and its complications

Fan MW, Tian JL, Chen T, Zhang C, Liu XR, Zhao ZJ, Zhang SH, Chen Y

ORIGINAL ARTICLE

Retrospective Study

Relationship between hemoglobin glycation index and risk of hypoglycemia in type 2 diabetes with time-2058 in-range in target

Lin BS, Liu ZG, Chen DR, Yang YL, Yang DZ, Yan JH, Zeng LY, Yang XB, Xu W

2070 Delayed treatment of diabetic foot ulcer in patients with type 2 diabetes and its prediction model Chen H, Xi Y

Observational Study

2081 Association between sensitivity to thyroid hormones and non-high-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus

Duan XY, Fu JL, Sun LN, Mu ZJ, Xiu SL



Contents

Monthly Volume 15 Number 10 October 15, 2024

Clinical and Translational Research

2093 Identification of immune feature genes and intercellular profiles in diabetic cardiomyopathy Zheng ZQ, Cai DH, Song YF

Basic Study

2111 Asiaticoside improves diabetic nephropathy by reducing inflammation, oxidative stress, and fibrosis: An in vitro and in vivo study

Zhuang LG, Zhang R, Jin GX, Pei XY, Wang Q, Ge XX

2123 Effect of cuproptosis on acute kidney injury after cardiopulmonary bypass in diabetic patients Deng XJ, Wang YN, Lv CB, Qiu ZZ, Zhu LX, Shi JH, Sana SRGL

SYSTEMATIC REVIEWS

Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 2135 diabetes: A systematic review with multiple network meta-regressions

Zhu JJ, Wilding JPH, Gu XS

LETTER TO THE EDITOR

Interleukin-35: A key player managing pre-diabetes and chronic inflammatory type 1 autoimmune 2147 diabetes

Chakraborty R, Mukherjee AK, Bala A

2152 Gut microbiota modulating therapy for diabetes mellitus should be individualized

Wang J, Wei HJ, Mao RF, Chang X



Contents

Monthly Volume 15 Number 10 October 15, 2024

ABOUT COVER

Peer Review of World Journal of Diabetes, Tao-Hsin Tung, PhD, Researcher, Director, Epidemiologist, Evidencebased Medicine Center, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou 317000, Zhejiang Province, China. dongdx@enzemed.com .

AIMS AND SCOPE

The primary aim of World Journal of Diabetes (WJD, World J Diabetes) is to provide scholars and readers from various fields of diabetes with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJD mainly publishes articles reporting research results and findings obtained in the field of diabetes and covering a wide range of topics including risk factors for diabetes, diabetes complications, experimental diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes, diabetic angiopathies, diabetic cardiomyopathies, diabetic coma, diabetic ketoacidosis, diabetic nephropathies, diabetic neuropathies, Donohue syndrome, fetal macrosomia, and prediabetic state.

INDEXING/ABSTRACTING

The WID is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 Edition of Journal Citation Reports® cites the 2023 journal impact factor (JIF) for WJD as 4.2; JIF without journal self cites: 4.1; 5-year JIF: 4.2; JIF Rank: 40/186 in endocrinology and metabolism; JIF Quartile: Q1; and 5year JIF Quartile: Q2.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Yu-Xi Chen; Production Department Director: Xu Guo; Cover Editor: Jia-Ru Fan.

NAME OF JOURNAL	INSTRUCTIONS TO AUTHORS					
World Journal of Diabetes	https://www.wjgnet.com/bpg/gerinfo/204					
ISSN	GUIDELINES FOR ETHICS DOCUMENTS					
ISSN 1948-9358 (online)	https://www.wignet.com/bpg/GerInfo/287					
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH					
June 15, 2010	https://www.wjgnet.com/bpg/gerinfo/240					
FREQUENCY	PUBLICATION ETHICS					
Monthly	https://www.wjgnet.com/bpg/GerInfo/288					
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT					
Lu Cai, Md. Shahidul Islam, Michael Horowitz	https://www.wignet.com/bpg/gerinfo/208					
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE					
https://www.wjgnet.com/1948-9358/editorialboard.htm	https://www.wignet.com/bpg/gerinfo/242					
PUBLICATION DATE	STEPS FOR SUBMITTING MANUSCRIPTS					
October 15, 2024	https://www.wignet.com/bpg/GerInfo/239					
COPYRIGHT	ONLINE SUBMISSION					
© 2024 Baishideng Publishing Group Inc	https://www.f6publishing.com					

© 2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: office@baishideng.com https://www.wjgnet.com



WJD

World Journal of **Diabetes**

Submit a Manuscript: https://www.f6publishing.com

World J Diabetes 2024 October 15; 15(10): 2147-2151

DOI: 10.4239/wjd.v15.i10.2147

ISSN 1948-9358 (online)

LETTER TO THE EDITOR

Interleukin-35: A key player managing pre-diabetes and chronic inflammatory type 1 autoimmune diabetes

Ratul Chakraborty, Ashis Kumar Mukherjee, Asis Bala

Specialty type: Endocrinology and metabolism

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification Scientific Quality: Grade C, Grade С Novelty: Grade B, Grade C

Creativity or Innovation: Grade B, Grade B Scientific Significance: Grade B, Grade C

P-Reviewer: Emran TB

Received: March 25, 2024 Revised: August 16, 2024 Accepted: August 26, 2024 Published online: October 15, 2024 Processing time: 185 Days and 1.7 Hours



Ratul Chakraborty, Ashis Kumar Mukherjee, Life Sciences Division, Institute of Advanced Study in Science and Technology, Guwahati 781035, Guwahati, Assam, India

Asis Bala, Pharmacology and Drug Discovery Research Laboratory, Division of Life Sciences, Institute of Advanced Study in Science and Technology, Guwahati 781035, Assam, India

Corresponding author: Asis Bala, PhD, Associate Professor, Pharmacology and Drug Discovery Research Laboratory, Division of Life Sciences, Institute of Advanced Study in Science and Technology, Vigyan Path, Guwahati 781035, Assam, India. asisbala@iasst.gov.in

Abstract

Interleukin-35 (IL-35) is a novel protein comprising IL-12 α and IL-27 β chains. The IL12A and *EBI3* genes are responsible for its production. The study of IL-35 has experienced a substantial increase in interest in recent years, as demonstrated by many research papers. Recent clinical studies have shown that individuals who do not have a C-peptide have notably reduced amounts of IL-35 in their blood serum. This is accompanied by a drop in the percentage of IL-35⁺ Treg cells, regulatory B cells, and CD8⁺ FOXP3⁺ cells that produce IL-35. This article emphasizes the potential significance of IL-35 expression in governing the immune response and its involvement in chronic inflammatory autoimmune diabetes in pancreatic inflammation. It demonstrates IL-35's ability to regulate cytokine proportions, modulate B cells, and protect against autoimmune diabetes. However, further investigation is necessary to ascertain the precise mechanism of IL-35, and meticulous planning is essential for clinical studies.

Key Words: Interleukin-35; Chronic inflammatory type diabetes; Autoimmune diabetes; Pancreatic inflammation; Gene disease association

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.



WJD | https://www.wjgnet.com

Core Tip: Studies suggest interleukin (IL)-35 protects against prediabetes and autoimmune diabetes by regulating immune system function. Development of type 1 diabetes (T1D) can be influenced by various cytokines produced by immune and pancreatic cells. Some cytokines, such as IL-10, transforming growth factor beta (TGF- β), IL-5, IL-4, IL-2, IL-15, IL-33, and IL-35, can stimulate regulatory cells in the immune system, releasing anti-inflammatory cytokines. Regulatory dendritic cells release IL-7, important for maintaining Tregs. In T1D, Tregs express IL-7R α . Inhibiting TGF- β and activating IFN- γ can increase TC, Th1, and Th17 cells, while TGF- β can stimulate Runx1 expression to convert Th1 cells into Th17 cells.

Citation: Chakraborty R, Mukherjee AK, Bala A. Interleukin-35: A key player managing pre-diabetes and chronic inflammatory type 1 autoimmune diabetes. *World J Diabetes* 2024; 15(10): 2147-2151 URL: https://www.wjgnet.com/1948-9358/full/v15/i10/2147.htm DOI: https://dx.doi.org/10.4239/wjd.v15.i10.2147

TO THE EDITOR

The study by Ping *et al*[1], published in 2024 in the *World Journal of Diabetes*, elucidates the etiology of prediabetes and its corresponding treatment medications. Nevertheless, the role of interleukin (IL)-35 in regulating the progression of prediabetes has not been investigated, which deserves due attention.

IL-35 has garnered considerable interest in recent years as a potential pivotal controller of diabetes, namely in prediabetes and chronic inflammatory autoimmune diabetes, which are progressively impacting children and adolescents across various locations globally[2,3]. Two separate genes encode IL-35 called IL12A and Epstein–Barr virus-induced 3 (EBI3)[4,5]. Both the genes IL-12A and EBI3 are networked with various diseases, as represented in Figure 1. The data in the PubMed database indicated a direct correlation between IL-35 and EBI3 genes in many immune-inflammatory, autoimmune, cancer, and endocrine diseases[6-8].



Figure 1 Schematic representation of interleukin-12A and Epstein-Barr virus-induced 3 individually and mutually networked with

WJD https://www.wjgnet.com

different diseases by white solid lines. Data were collected from the PubMed database. The disease-gene association is searched in the DisGeNET database v 7.0 for gene-disease associations, whereas the "N_PMIDs (citation)" \geq 3 were considered, and a gene-disease target network was created and analyzed using CYTOSCAPE version 3.10.0. Schematic representation of networking in Figure 1, in which interleukin-12A and Epstein–Barr virus-induced 3 are found to be individually and mutually networked by solid white lines.

Further, we selected 5 protein/enzyme markers clinically identified with IL12A and EBI3 from the PubMed database. We then searched for their UniProt ID and human gene names in the UniProt databases and looked for their disease associations in the DisGeNET database v7.0. Gene-disease associations with N_PMIDs (citation) greater than or equal to 10 were considered. Finally, we created a gene-disease target network using CYTOSCAPE version 3.10.0[9]. The schematic representation of networking of the total of five genes named ADIPOQ, CRP, IL18, IL1RN, and SERPINE1 encodes the protein Progestin and adipoQ receptor family member 3, C-reactive protein, IL-18, IL-1 receptor antagonist protein, and SERPINE1 mRNA-binding protein 1, respectively are shown in Figure 2.

P	hospholipas	е		60				Acute	Acute	Acute	Acute		
	A2,		11-6	kDa A	DIPO	QAHSG	ASPG	Chest	Coronary	lymphocyti	cnyocardia	Acute	lenoc ar cinoma
IL IRIN	membrane	IL-IRA	lysop	hospholip	base	ABA.	The	Syndrome	Syndrome	e leukemia	infarction	pancreatit	5
Adult	associated	Age		X		11 M M	STAR		Andia		rteriospero	eie	
Acute	Adult-Onset	related .	AUCTA	Izheimer's	5	Ankylosing		Anxiety	Aortic	Annomilale		Artheritio	Arthritis,
Lymphocyti	ic Discose	macular	2-HS-glycop	Disease	Anemia	spondylitis	Anxiety	Disorders	Abdomina	Abbeurgicin	S	Arunnus	Psoriatic
Leukemia	Disease	generatio	n	APS.		计错误力	HO IS	PAG	Abdomina		-11		
	Athe	Ath	erothrombo	SIS	482AFH	计理论	TT XF	1 All	Bacterial		XII		CATARACT,
Arthropath	y Asthma			Atrial	Autommun	e Axial	Bacteremia	a	Sepsis		Bipolar	Breast	ANTERIOR
	1000			Fioniauon	Discases	ponuyioarum	TAT:	Intections	nouthorn		Disorder	Carcinom	POLAR
		Contraction of			arabravas	Ghildhood	1.111/20	Chronic	newborn	Chronic	1		
CDB		arcinoma	Carcinoma,	ardiovascul	af acciden	Acute	Chronic	Obstructive	Chronic	kidney	Colon	Colorecta	Community
CRP	arcinogenesi	IS OF	Contan	Diseases	DAL 1	ymphoblas	tig:	Airway	diopathic	disease	Carcinoma	Carcinom	acquired
101	Co	onventiona	Fbimelia			Leukemia	Diseases	Disease	unicana	stage		MIL	pneumonia
a	Congestive	(Clear	Coro	nary	Coronary	1200	####	1 PM	++	5		11/11	
Congenita	heart	Cell)	Arte		Artary	Crohn	Deep	MAG	Delirium	Dementia	Depresse		Depressive
hypotibrinogen	emia	Renal	Dise	aso	Disease	Disease	Vein	Degenera	ative	16-	mood D	epressive	disorder
		Cen	684496k	AN ALE	DAT D	Diabetic	Infombos	s polyanni	nus	+-+	5	Symptoms	// /
Dermatitis		accinoma	Arterioscleros	A B B	Diabetic	Retinopath	Duodenal	フィギリン	N V	Endometria	Endothelia	at the	Esophageal
Atopic	E HHH		Artemoscieros	KANK.	Nephropath	WALNP	Ulcer	Dyslipidemia	astczema	Carcinoma	dysfunctio	ndotoxem	carcinoma
	Helicobacter	CULT X	88886	CL&RC	N. C.	1 BARE	771	A-M	144	16	Gestat	ional	11
	pylori	Factor	Familial	SK SS	SSD	Fatty	AHE:	11 Ato	474	1000	Diabo	tes	18
FGB	FMOK	. 🎽 M	editerranea	rFatigue	Fatty	Liver	Fever	Fibrinogen	Fibrosis	osamine-3-	kinase (Glioblaston	na Glioma
TA	pylori)	Leiden	Fever	imo	Liver	enQisease	AND	FIEM.	Liver	At-			
K	infection	mutation	XLIM.	888 <u>88</u>	virus	BUCK	18M2	1.44	All L	tett	1-1		
Heart	in	Hepatitis	Hepatitis	Hepatitis	(HIV).	1944	and the second second	Hypertensiv	ertriglycerid	lemia			11 40
failure	conditions	B	COR		RICE	lyperglycely	parinsulini	disease	Hypoadip	onectinem	palbumine	emiaL=18	ILIO
1	classified	MAN	HANI IN	Chronic	infection	MARK .	HX-CC	くりろん	HH AL	AL A	1	South	
	and	UNNY	Impaired	& / Iu	meanerge by	X A A X	1.19.14	はしろ	A-AL	Kidney	Kidney	XX	XX
11 1RM	IL6R	Impaired	glucose In	flammatio	Biager	Iron	Ischemic	Joint	Kidney	Failure,	Failure, I	eukocytos	læukopenia
	unspecified	cognition	tolerance	XIIIX	Diseases	deliciency	SHOKE	tendemess	SUISeases	Mandiant	Chronic	< VM	W/I
1	site	ABBA	AH LA	ALTIT S		XXXX	11-62	オンドリン	Malignant	neoplasm	Malignant	Malignan	Malignant
	Liver	Liver	Liver_	Lupus /	Macropha	ge Major	CARD &	Malignant	neoplasm	of	neoplasm	neoplasm	neoplasm
Lipodystrop	Cirrhosis c	arcinoma	diseases	thematos	Sundram	Disordar	Malaria	Neoplasms	s of	colon	of	of	of
	N M NU	1111	PINUS!	Systemic	Synulonn	Disoluel	W/2	×1-11.	breast	and/or	esophagu	s lung	prostate
Malignant	Malignant	1111	NAM I	1022	さぼくさつ	Metabolic	Metastatic	Metastatic	MAN	ncoentaub	006	XV 1	41
neoplasm	tumor	Mammary	Depreseied	Mental	Metabolic	Syndrome	Renal	Renar	Miscarriage	e Nodo	Nulliple	Myocardia	Invocardial
stomach	colon	eoplasma	Jepression	aterioratio	Diseases	X	Cancer	Carcinoms	XX	Syndrome	Scierosis	nnarcuon	Ischemia
Stomach	COLON A	Non-Small	on-alcoholid	Ato	1 A S	THE	Cancer	DALA	1/1/1	Syncionic	DESS.	X HII	AIII
Neoplasm	Magaza	Cell	Fatty	obath	Obesity,	Ontone colit	DAL	PAI-T	PAI-1	DIARCOA	Opin	Deneratit	Bariadantitia
Metastasis	Reoplasins	Lung	Liver	Obesity	Morbid	Osteomyein	SPARE	alumorph	olymorphis	Sm	1 Pan	Pancreau	senodonuus
	¢	Carcinoma	Disease	Dr	Precurso	AA &	AXA	Primary	1-1-1	きませい	LA HE		8/18
Peripheral			PolycysRos	st-Trauma	tic Cell	-V/	Primary	malignant	1-16	HHH	THE PAR		
Arterial	Pla2g2a P	neumonia	Ovary	StressL	mphoblas	stic	malignant	neoplasm	Prostate	Psoriasis	Fulmonar	Kneumate	RPINE1
Diseases		T	Syndrome	Disorder	Leukemia	a vemenua	neoplasm	lo	carcinoina	AA	FIDIOSIS	Aunnas	
ST		HI	1117	Sepsis	Lymphom	a	Squamous	s lung		1 All	Systemic	KIL	\checkmark
segment	Constala	hisohan	InContin	of	Contingent	Sleep	Cell	Instalantal	Stomach	Cumant	nflammato	nSystemic	mhondonala
elevation	Sarcoloosis	nizophren	asepsis	the	Septreem	a Apriea,	carcinoma	reatonepati	Carcinoma	a Synovitis	Response	Sclerodern	a
infarction		H		newborn	1-	Obstructive	esonhagu	2	-14		Syndrome		
marcuon	4	Tumor	Tumor	Hagenting	Halaalaa	Vacaulas	Vacaulas	Vanaura	Vinia				
Thrombophi	laberculosis	Cell ,	Progression	Colitie	Depreseio	Disease	vascular	mboombo	Binesee		Pior	mork	ore
		Invasion	10910351011	Contra	-opiosal0	1013003050	Jucificatio	unicoenioc	1000305		DIUI	Iark	615

Figure 2 Schematic representation of networking of the 5 genes encodes 5 unique protein/enzymatic markers. A total of 5 clinically identified protein/enzyme markers were identified from the PubMed database. Next, their UniProt ID and human gene names were searched in the UniProt databases, and their disease associations were found in the DisGeNET database v7.0. A note on gene-disease associations with N_PMIDs (citation) greater than or equal to 10 was taken. Lastly, the gene-disease target network was constructed and analyzed using CYTOSCAPE version 3.10.0.

Baishidena® WJD | https://www.wjgnet.com

The network pharmacological analysis revealed that these five genes, highlighted in the figure, exhibited the most significant interaction with the disease. The PubMed database establishes a correlation between 5 genes and various disorders, encompassing immune-inflammatory, autoimmune, cancer, and endocrine diseases.

Based on several PubMed literature searches, there is a direct correlation between proinflammatory mediators such as CRP and IL-6R, which has been re-validated through networking. As a result, IL-35, an anti-inflammatory immune suppressant, may help counteract the proinflammatory signals that occur during prediabetes, diabetes, and its complications.

KEY POINTS

IL-35 is a protective factor against prediabetes and plays a significant role in macrophage polarization[10]. Treg and Th1 cells are crucial for this protection[11]. Studies on non-obese diabetic mice have revealed that IL-35 expression reduces conventional T cells, dendritic cells, and Treg cells against beta cells[12]. The administration of IL-35 also reduces the number of Th1 and Th17 cells and IFN-γ or IL-17A-expressing CD8+ T cells[13]. Thereby, IL-35 plays a critical regulatory role in T1D by decreasing the infiltration of mononuclear cells in the islets [14,15]. Clinical research has provided additional insights, indicating that C-peptide-negative patients exhibit markedly lower serum levels of IL-35[8-13]. This decrease is associated with a simultaneous reduction in the proportion of IL-35+ Treg cells, IL-35+ regulatory B cells, and IL-35-producing CD8+ FOXP3+ cells[15,16].

CONCLUSION

The results above emphasize the possible importance of IL-35 expression in regulating the immune response and its involvement in the autoimmune mechanisms underlying type 1 diabetes. Immunotherapy with IL-35 has demonstrated encouraging outcomes in combating the consequences of prediabetes and diabetes. Research indicates that IL-35 can alter the balance of cytokines, modulate the activity of B cells, and offer defense against autoimmune diabetes. Nevertheless, additional investigation is necessary to ascertain the precise mechanism of action, accompanied by meticulous design of clinical studies.

ACKNOWLEDGEMENTS

The authors sincerely thank the Institute of Advanced Study in Science and Technology (IASST) and the Department of Science and Technology, Government of India for their assistance and contributions.

FOOTNOTES

Author contributions: Bala A was responsible for planning and writing; Chakraborty R systematically formatted the manuscript; Mukherjee AK revised the manuscript with data analysis.

Conflict-of-interest statement: All of the authors have no relevant financial or non-financial interests to disclose.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country of origin: India

ORCID number: Asis Bala 0000-0002-2148-2331.

S-Editor: Liu JH L-Editor: Filipodia P-Editor: Zhang L

REFERENCES

- Ping WX, Hu S, Su JQ, Ouyang SY. Metabolic disorders in prediabetes: From mechanisms to therapeutic management. World J Diabetes 2024; 15: 361-377 [PMID: 38591088 DOI: 10.4239/wjd.v15.i3.361]
- Ye C, Yano H, Workman CJ, Vignali DAA. Interleukin-35: Structure, Function and Its Impact on Immune-Related Diseases. J Interferon 2

WJD | https://www.wjgnet.com

Cytokine Res 2021; 41: 391-406 [PMID: 34788131 DOI: 10.1089/jir.2021.0147]

- Zysk W, Gleń J, Trzeciak M. Current Insight into the Role of IL-35 and Its Potential Involvement in the Pathogenesis and Therapy of Atopic 3 Dermatitis. Int J Mol Sci 2022; 23 [PMID: 36555351 DOI: 10.3390/ijms232415709]
- Zhang SM, Liang J, Xia JP, Li L, Zheng L, Wang YL, Li YH, Li Y, Lu Y. Interleukin 35: protective role and mechanism in type 1 diabetes. 4 Cent Eur J Immunol 2023; 48: 48-53 [PMID: 37206590 DOI: 10.5114/ceji.2023.125043]
- Lu J, Liu J, Li L, Lan Y, Liang Y. Cytokines in type 1 diabetes: mechanisms of action and immunotherapeutic targets. Clin Transl Immunology 5 2020; 9: e1122 [PMID: 32185024 DOI: 10.1002/cti2.1122]
- Cano-Cano F, Gómez-Jaramillo L, Ramos-García P, Arroba AI, Aguilar-Diosdado M. IL-1ß Implications in Type 1 Diabetes Mellitus 6 Progression: Systematic Review and Meta-Analysis. J Clin Med 2022; 11 [PMID: 35268394 DOI: 10.3390/jcm11051303]
- Zhang J, Zhang Y, Wang Q, Li C, Deng H, Si C, Xiong H. Interleukin-35 in immune-related diseases: protection or destruction. Immunology 7 2019; 157: 13-20 [PMID: 30681737 DOI: 10.1111/imm.13044]
- Wetzel A, Scholtka B, Schumacher F, Rawel H, Geisendörfer B, Kleuser B. Epigenetic DNA Methylation of EBI3 Modulates Human 8 Interleukin-35 Formation via NFkB Signaling: A Promising Therapeutic Option in Ulcerative Colitis. Int J Mol Sci 2021; 22 [PMID: 34069352 DOI: 10.3390/ijms22105329]
- 9 Devroy P, Chatterjee SK, Singh R, Mohapatra S, Haldar S, Mukherjee AK, Bala A. Candy leaf - Stevia rebaudiana (Bertoni) Bertoni attenuated LPS-induced protein kinase C phosphorylation in mouse macrophages cells: Target search by network pharmacology and validation using ex vivo and in vivo assays. Food Biosci 2024; 61: 104809 [DOI: 10.1016/j.fbio.2024.104809]
- Chakraborty R, Mukherjee AK, Bala A. Breakthroughs in road mapping IL-35 mediated immunotherapy for type-1 and autoimmune diabetes 10 mellitus. Cytokine 2024; 181: 156692 [PMID: 38986251 DOI: 10.1016/j.cyto.2024.156692]
- 11 Espes D, Singh K, Sandler S, Carlsson PO. Increased Interleukin-35 Levels in Patients With Type 1 Diabetes With Remaining C-Peptide. Diabetes Care 2017; 40: 1090-1095 [PMID: 28620093 DOI: 10.2337/dc16-2121]
- Singh K, Martinell M, Luo Z, Espes D, Stålhammar J, Sandler S, Carlsson PO. Cellular immunological changes in patients with LADA are a 12 mixture of those seen in patients with type 1 and type 2 diabetes. Clin Exp Immunol 2019; 197: 64-73 [PMID: 30843600 DOI: 10.1111/cei.13289]
- Ouyang H, Wen J, Song K. Decreased interleukin-35 levels and CD4(+)EBI3(+) T cells in patients with type 1 diabetes and the effects of the 13 antibody against CD20 (rituximab). Arch Med Sci 2021; 17: 258-261 [PMID: 33488880 DOI: 10.5114/aoms.2020.101510]
- Luo Z, Lundin S, Mejia-Cordova M, Hassani I, Blixt M, Hjelmqvist D, Lau J, Espes D, Carlsson PO, Sandler S, Singh K. Interleukin-35 14 Prevents Development of Autoimmune Diabetes Possibly by Maintaining the Phenotype of Regulatory B Cells. Int J Mol Sci 2021; 22 [PMID: 34884797 DOI: 10.3390/ijms222312988]
- Sawant DV, Hamilton K, Vignali DA. Interleukin-35: Expanding Its Job Profile. J Interferon Cytokine Res 2015; 35: 499-512 [PMID: 15 25919641 DOI: 10.1089/jir.2015.0015]
- Yan A, Zhang Y, Wang X, Cui Y, Tan W. Interleukin 35 regulates interleukin 17 expression and T helper 17 in patients with proliferative 16 diabetic retinopathy. Bioengineered 2022; 13: 13293-13299 [PMID: 35635032 DOI: 10.1080/21655979.2022.2080367]



WJD https://www.wjgnet.com



Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: office@baishideng.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

